KR20230054451A - 길항작용 cd40 모노클로날 항체를 사용하여 자가면역 질환을 치료하는 방법 - Google Patents

길항작용 cd40 모노클로날 항체를 사용하여 자가면역 질환을 치료하는 방법 Download PDF

Info

Publication number
KR20230054451A
KR20230054451A KR1020237009804A KR20237009804A KR20230054451A KR 20230054451 A KR20230054451 A KR 20230054451A KR 1020237009804 A KR1020237009804 A KR 1020237009804A KR 20237009804 A KR20237009804 A KR 20237009804A KR 20230054451 A KR20230054451 A KR 20230054451A
Authority
KR
South Korea
Prior art keywords
ser
val
thr
lys
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237009804A
Other languages
English (en)
Korean (ko)
Inventor
잉 예
우르비 아라스
니디 샤르다
메리 스트루더스
카렌 프라이스
이합 기르기스
아베라 푸라
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20230054451A publication Critical patent/KR20230054451A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
KR1020237009804A 2020-08-25 2021-08-25 길항작용 cd40 모노클로날 항체를 사용하여 자가면역 질환을 치료하는 방법 Pending KR20230054451A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063070209P 2020-08-25 2020-08-25
US63/070,209 2020-08-25
PCT/US2021/047610 WO2022046942A1 (en) 2020-08-25 2021-08-25 Method of treating an autoimmune disease with antagonistic cd40 monoclonal antibodies

Publications (1)

Publication Number Publication Date
KR20230054451A true KR20230054451A (ko) 2023-04-24

Family

ID=77693641

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237009804A Pending KR20230054451A (ko) 2020-08-25 2021-08-25 길항작용 cd40 모노클로날 항체를 사용하여 자가면역 질환을 치료하는 방법

Country Status (11)

Country Link
US (1) US20230331860A1 (cg-RX-API-DMAC10.html)
EP (1) EP4204099A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023539736A (cg-RX-API-DMAC10.html)
KR (1) KR20230054451A (cg-RX-API-DMAC10.html)
CN (1) CN116322761A (cg-RX-API-DMAC10.html)
AU (1) AU2021331087A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023002803A2 (cg-RX-API-DMAC10.html)
CA (1) CA3190727A1 (cg-RX-API-DMAC10.html)
IL (1) IL300765A (cg-RX-API-DMAC10.html)
MX (1) MX2023002093A (cg-RX-API-DMAC10.html)
WO (1) WO2022046942A1 (cg-RX-API-DMAC10.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
TWI788340B (zh) * 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
SG11201909941QA (en) * 2017-05-02 2019-11-28 Merck Sharp & Dohme Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
JP7301002B2 (ja) * 2017-05-30 2023-06-30 ブリストル-マイヤーズ スクイブ カンパニー 抗lag-3抗体または抗lag-3抗体および抗pd-1もしくは抗pd-l1抗体を含む組成物
EA202090063A1 (ru) * 2017-06-16 2020-04-03 Бристоль-Мейерз Сквибб Компани Композиции и способы для лечения таупатий
EP3704158A1 (en) * 2017-11-03 2020-09-09 Novartis AG Anti-cd40 antibodies for use in treatment of sjögren's syndrome
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos

Also Published As

Publication number Publication date
CA3190727A1 (en) 2022-03-03
AU2021331087A1 (en) 2023-04-20
EP4204099A1 (en) 2023-07-05
IL300765A (en) 2023-04-01
JP2023539736A (ja) 2023-09-19
US20230331860A1 (en) 2023-10-19
WO2022046942A1 (en) 2022-03-03
MX2023002093A (es) 2023-03-15
CN116322761A (zh) 2023-06-23
BR112023002803A2 (pt) 2023-03-14

Similar Documents

Publication Publication Date Title
KR102627246B1 (ko) 길항작용 cd40 모노클로날 항체 및 그의 용도
KR102713355B1 (ko) 길항작용 cd40 모노클로날 항체 및 그의 용도
EP3299392B1 (en) Antibodies directed against the alpha chain of il7 receptor - their use for the preparation of drug candidates
JP2023103456A (ja) Il-7rアルファサブユニットに対する抗体及びその使用
CN106061999B (zh) Il-21抗体
EP2512511B1 (en) Humanized antibodies against human il-22ra
JP2018526974A (ja) Pdl−1抗体、その医薬組成物及びその使用
AU3369701A (en) Antibodies to human il-1beta
CA2321165A1 (en) Antibodies against human cd40
EA031849B1 (ru) Антитела к ox40 и способы их применения
CN108473568A (zh) 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子
JP7736783B2 (ja) エンゲージャを含む薬物治療剤の開発及び応用
KR20230034960A (ko) Lag3에 결합하는 항체 및 그 용도
JP2026027375A (ja) T細胞アダプター治療剤の開発及び使用
JP2023532248A (ja) 免疫関連疾患のためのtigitに対するヒトモノクローナル抗体
JP7278623B2 (ja) 抗cd27抗体およびその使用
US20230331860A1 (en) Method of Treating an Autoimmune Disease with Antagonistic CD40 Monoclonal Antibodies
TW202229355A (zh) 抗tnfr2抗體及其應用
HK40075900B (en) Pd1 and vegfr2 dual-binding agents
HK40075900A (en) Pd1 and vegfr2 dual-binding agents

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230322

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240823

Comment text: Request for Examination of Application